ClinicalTrials.gg
CompletedNCT03518086Updated May 31, 2025Results posted

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

A Phase 3 interventional study of Mirikizumab and Placebo in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 502 sites in 35 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,281
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.

Enrollment
2nd of 13
1,281 · median 172
Started
2018
with 2 others
Phase 3
7 of 13
1 open now
Registered
2nd of 13
by date
Lead sponsor
9 of 13
Eli Lilly and Company

Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 7 in phase 3, and was the 2nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing mirikizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Interleukin-23 (IL-23) antibody
  • IL-23p19
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of UC for at least 3 months prior to baseline.
  • Confirmed diagnosis of moderately or severely active UC, as assessed by the modified Mayo score (MMS).
  • Demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic therapy for UC.
  • If female, must meet the requirements.

Exclusion criteria

Exclusion Criteria:

  • Participants with a current diagnosis of Crohn's disease or inflammatory bowel disease-unclassified (indeterminate colitis).
  • Participants with a previous colectomy.
  • Participants with current evidence of toxic megacolon.
  • Prior exposure to anti-IL12p40 antibodies (e.g. ustekinumab) or anti-IL-23p19 antibodies (e.g. risankizumab, brazikumab, guselkumab or tildrakizumab).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,281 participants (actual)

Study arms

  • Placebo comparator
    Placebo Intravenous (IV) Every 4 Weeks (Q4W)

    Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.

    Drug: Placebo

  • Experimental
    300 Milligram (mg) Mirikizumab IV Q4W

    300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.

    Drug: Mirikizumab

  • Placebo comparator
    Placebo IV Q4W Maximum Extended Enrollment (ME2)

    Placebo given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.

    Drug: Placebo

  • Experimental
    300 mg Mirikizumab IV Q4W ME2

    300 mg mirikizumab given as an IV infusion Q4W on Weeks 0, 4, 8 for 12 weeks.

    Drug: Mirikizumab

Interventions

  • Administered IV

    Also known as: LY3074828

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Remission at Week 12

    Clinical remission at week 12 is defined as achieving a modified Mayo score (MMS) subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability), excluding consideration of Physician's Global Assessment (PGA). Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The confidence interval of 99.88% was chosen to match the significance level.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants With Clinical Response at Week 12

    Clinical response at week 12 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of \>= 2 points and \>=30% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1.The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration).The MMS ranges from 0 to 9 points,with higher scores representing more severe disease. The confidence interval of 99.88% was chosen to match the significance level.

    Time frame: Week 12

  2. Percentage of Participants With Endoscopic Remission at Week 12

    Endoscopic remission at week 12 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 12. Endoscopy subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The Mayo endoscopic score ranges from 0 to 3 points, with higher scores representing more severe disease. The confidence interval of 99.88% was chosen to match the significance level.

    Time frame: Week 12

  3. Percentage of Participants With Symptomatic Remission at Week 12

    Symptomatic remission at week 12 is defined as a Mayo subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed). The confidence interval of 99.88% was chosen to match the significance level.

    Time frame: Week 12

  4. Percentage of Participants With Symptomatic Response at Week 12

    Symptomatic response at week 12 is defined as ≥30% decrease from baseline in the sum of stool frequency and rectal bleeding subscores. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed). The sum of stool frequency and rectal bleeding subscores ranges from 0 to 6.

    Time frame: Week 12

  5. Percentage of Participants With Histologic Remission at Week 12

    Histologic remission was assessed using the Geboes histologic scoring system developed for assessment of histologic disease activity in ulcerative colitis. Remission was defined as Geboes histological subscore of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration).

    Time frame: Week 12

  6. Percentage of Participants With Endoscopic Response at Week 12

    Endoscopic response at week 12 is defined as achieving at least a 1 point decrease from baseline in the Mayo endoscopic subscore. The Mayo endoscopic subscore ranges from 0 to 3 points, with higher scores representing more severe disease.

    Time frame: Week 12

  7. Change From Baseline to Week 12 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS)

    The Urgency NRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).Higher scores indicate more severe urgency. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes: treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).

    Time frame: Baseline, Week 12

  8. Change From Baseline to Week 12 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

    The IBDQ is a 32-item participant-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function (Guyatt et al. 1989). Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. Least square (LS) Mean was calculated using analysis of covariance (ANCOVA) model for post-baseline measures: The ANCOVA model includes: treatment, baseline value, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).

    Time frame: Baseline, Week 12

  9. Change From Baseline to Week 12 in Fecal Calprotectin

    Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes: treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).

    Time frame: Baseline, Week 12

  10. Pharmacokinetics (PK): Clearance of Mirikizumab

    Clearance of mirikizumab was evaluated. Clearance is estimated based on concentration data collected in the time frame of 0-12 weeks.

    Time frame: Predose on week 0, week 4, week 8 and post dose on week 0, 4 and 12

07

Results

Posted Feb 28, 2022

Participant flow

Main study: Participants were randomized in a 3:1 ratio to 300 milligrams (mg) of mirikizumab intravenously (IV) every 4 weeks (Q4W) or placebo IV Q4W. China Maximized Extended Enrollment (ME2): This is an extension phase of the main study, with an additional 166 participants enrolled in China. Safety was monitored and data was reported under Adverse Events (AE) section.

Participant flow — Overall Study
MilestonePlacebo IV Q4W300 mg Mirikizumab IV Q4WPlacebo IV Q4W ME2 Cohort300 mg Mirikizumab IV Q4W ME2 Cohort
Started32295941125
Received at least one dose of study drug32195841125
Completed28592036116
Not completed373959
Withdrew: Adverse event231532
Withdrew: Withdrawal by subject8510
Withdrew: Lack of efficacy5502
Withdrew: Protocol violation1513
Withdrew: Lost to follow-up0300
Withdrew: Insufficient diary data0200
Withdrew: Non- compliance to protocol0100
Withdrew: Covid-19 related study disruption0200
Withdrew: Site terminated by sponsor0100
Withdrew: Pregnancy0002

Outcome measures

PrimaryPercentage of Participants With Clinical Remission at Week 12

Clinical remission at week 12 is defined as achieving a modified Mayo score (MMS) subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability), excluding consideration of Physician's Global Assessment (PGA). Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The confidence interval of 99.88% was chosen to match the significance level.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Week 12
percentage of participantsPlacebo IV Q4W300 mg Mirikizumab IV Q4W
Percentage of Participants With Clinical Remission at Week 1213.3 (6.9 to 19.6)24.2 (19.5 to 28.9)
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · Cochran-Mantel-Haenszel · p = 0.00006 · Risk difference (rd): 11.1 · 99.875% CI 3.2 to 19.1
SecondaryPercentage of Participants With Clinical Response at Week 12

Clinical response at week 12 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of \>= 2 points and \>=30% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1.The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration).The MMS ranges from 0 to 9 points,with higher scores representing more severe disease. The confidence interval of 99.88% was chosen to match the significance level.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Week 12
percentage of participantsPlacebo IV Q4W300 mg Mirikizumab IV Q4W
Percentage of Participants With Clinical Response at Week 1242.2 (32.9 to 51.5)63.5 (58.2 to 68.8)
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · Cochran-Mantel-Haenszel · p = <0.00001 · Risk difference (rd): 21.4 · 99.875% CI 10.8 to 32.0
SecondaryPercentage of Participants With Endoscopic Remission at Week 12

Endoscopic remission at week 12 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 12. Endoscopy subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The Mayo endoscopic score ranges from 0 to 3 points, with higher scores representing more severe disease. The confidence interval of 99.88% was chosen to match the significance level.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Remission at Week 12
percentage of participantsPlacebo IV Q4W300 mg Mirikizumab IV Q4W
Percentage of Participants With Endoscopic Remission at Week 1221.1 (13.4 to 28.8)36.3 (31.0 to 41.6)
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · Cochran-Mantel-Haenszel · p = <0.00001 · Risk difference (rd): 15.4 · 99.875% CI 6.3 to 24.5
SecondaryPercentage of Participants With Symptomatic Remission at Week 12

Symptomatic remission at week 12 is defined as a Mayo subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed). The confidence interval of 99.88% was chosen to match the significance level.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Remission at Week 12
percentage of participantsPlacebo IV Q4W300 mg Mirikizumab IV Q4W
Percentage of Participants With Symptomatic Remission at Week 1227.9 (22.8 to 33.0)45.5 (42.2 to 48.8)
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 17.5 · 99.875% CI 11.4 to 23.6
SecondaryPercentage of Participants With Symptomatic Response at Week 12

Symptomatic response at week 12 is defined as ≥30% decrease from baseline in the sum of stool frequency and rectal bleeding subscores. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed). The sum of stool frequency and rectal bleeding subscores ranges from 0 to 6.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Response at Week 12
percentage of participantsPlacebo IV Q4W300 mg Mirikizumab IV Q4W
Percentage of Participants With Symptomatic Response at Week 1252.4 (46.7 to 58.1)72.0 (69.0 to 75.0)
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 20.2 · 95% CI 13.8 to 26.6
SecondaryPercentage of Participants With Histologic Remission at Week 12

Histologic remission was assessed using the Geboes histologic scoring system developed for assessment of histologic disease activity in ulcerative colitis. Remission was defined as Geboes histological subscore of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Histologic Remission at Week 12
percentage of participantsPlacebo IV Q4W300 mg Mirikizumab IV Q4W
Percentage of Participants With Histologic Remission at Week 1215.6 (11.5 to 19.8)29.3 (26.2 to 32.3)
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 13.7 · 95% CI 8.6 to 18.7
SecondaryPercentage of Participants With Endoscopic Response at Week 12

Endoscopic response at week 12 is defined as achieving at least a 1 point decrease from baseline in the Mayo endoscopic subscore. The Mayo endoscopic subscore ranges from 0 to 3 points, with higher scores representing more severe disease.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Response at Week 12
percentage of participantsPlacebo IV Q4W300 mg Mirikizumab IV Q4W
Percentage of Participants With Endoscopic Response at Week 1236.1 (30.6 to 41.5)55.4 (52.1 to 58.7)
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · Cochran-Mantel-Haenszel · p = <0.00001 · Risk difference (rd): 19.5 · 95% CI 13.2 to 25.8
SecondaryChange From Baseline to Week 12 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS)

The Urgency NRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).Higher scores indicate more severe urgency. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes: treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS)
score on a scalePlacebo IV Q4W300 mg Mirikizumab IV Q4W
Change From Baseline to Week 12 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS)-1.63 ± 0.141-2.59 ± 0.083
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · Mixed Models Analysis · p = <0.00001 · Mean difference (net): -0.95 · 99.875% CI -1.47 to -0.44The confidence interval of 99.875 % was chosen to match the significance level.
SecondaryChange From Baseline to Week 12 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

The IBDQ is a 32-item participant-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function (Guyatt et al. 1989). Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. Least square (LS) Mean was calculated using analysis of covariance (ANCOVA) model for post-baseline measures: The ANCOVA model includes: treatment, baseline value, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
score on a scalePlacebo IV Q4W300 mg Mirikizumab IV Q4W
Change From Baseline to Week 12 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score25.21 ± 1.79838.42 ± 1.108
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · ANCOVA · p = <0.001 · Mean difference (net): 13.21 · 95% CI 9.28 to 17.15
SecondaryChange From Baseline to Week 12 in Fecal Calprotectin

Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes: treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), baseline disease activity (MMS: \[4-6\] or \[7-9\]), and region (North America/Europe/Other).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · milligram per kilogram (mg/kg)
Change From Baseline to Week 12 in Fecal Calprotectin
milligram per kilogram (mg/kg)Placebo IV Q4W300 mg Mirikizumab IV Q4W
Change From Baseline to Week 12 in Fecal Calprotectin-939.69 ± 196.557-1875.29 ± 116.138
Statistical analysis
  • Placebo IV Q4W vs 300 mg Mirikizumab IV Q4W · Mixed Models Analysis · p = <0.001 · Mean difference (net): -935.60 · 95% CI -1363.64 to -507.55
SecondaryPharmacokinetics (PK): Clearance of Mirikizumab

Clearance of mirikizumab was evaluated. Clearance is estimated based on concentration data collected in the time frame of 0-12 weeks.

Time frame:
Predose on week 0, week 4, week 8 and post dose on week 0, 4 and 12
Reported as:
Geometric mean · Liters per Hour (L/h)
Pharmacokinetics (PK): Clearance of Mirikizumab
Liters per Hour (L/h)300 mg Mirikizumab IV Q4W
Pharmacokinetics (PK): Clearance of Mirikizumab0.0224 ± 38

Adverse events

Collected over Baseline Up to week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo IV Q4W0/321 (0%)17/321 (5.3%)18/321 (5.6%)
300 Mirikizumab IV Q4W0/958 (0%)27/958 (2.8%)31/958 (3.2%)
Placebo IV Q4W ME2 Cohort0/41 (0%)7/41 (17.1%)11/41 (26.8%)
300 mg Mirikizumab IV Q4W ME2 Cohort0/125 (0%)10/125 (8%)25/125 (20%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventPlacebo IV Q4W300 Mirikizumab IV Q4WPlacebo IV Q4W ME2 Cohort300 mg Mirikizumab IV Q4W ME2 Cohort
Colitis ulcerativeGastrointestinal disorders10/3218/9584/414/125
AnaemiaBlood and lymphatic system disorders1/3211/9581/410/125
PneumoniaInfections and infestations0/3212/9581/413/125
OsteoarthritisMusculoskeletal and connective tissue disorders0/3210/9581/410/125
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3210/9581/410/125
DyspnoeaRespiratory, thoracic and mediastinal disorders0/3210/9581/410/125
Rectal polypGastrointestinal disorders0/3210/9580/411/125
Cytomegalovirus infectionInfections and infestations0/3210/9580/411/125
PharyngitisInfections and infestations0/3210/9580/411/125
Joint injuryInjury, poisoning and procedural complications0/3210/9580/411/125
Most frequent other events
Most frequent other events
EventPlacebo IV Q4W300 Mirikizumab IV Q4WPlacebo IV Q4W ME2 Cohort300 mg Mirikizumab IV Q4W ME2 Cohort
Upper respiratory tract infectionInfections and infestations0/3210/9584/4115/125
AnaemiaBlood and lymphatic system disorders18/32131/9584/418/125
Colitis ulcerativeGastrointestinal disorders0/3210/9583/413/125

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo IV Q4W300 mg Mirikizumab IV Q4WPlacebo IV Q4W ME2 Cohort300 mg Mirikizumab IV Q4W ME2 CohortTotal
Mean41.3 ± 13.7842.8 ± 13.8349.4 ± 15.4344.0 ± 13.8842.8 ± 13.92
Sex: Female, Male
Sex: Female, Male(Participants)Placebo IV Q4W300 mg Mirikizumab IV Q4WPlacebo IV Q4W ME2 Cohort300 mg Mirikizumab IV Q4W ME2 CohortTotal
Female1403671346566
Male1825922879881
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo IV Q4W300 mg Mirikizumab IV Q4WPlacebo IV Q4W ME2 Cohort300 mg Mirikizumab IV Q4W ME2 CohortTotal
Hispanic or Latino9220031
Not Hispanic or Latino27922584228
Unknown or Not Reported28684516411188
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo IV Q4W300 mg Mirikizumab IV Q4WPlacebo IV Q4W ME2 Cohort300 mg Mirikizumab IV Q4W ME2 CohortTotal
American Indian or Alaska Native2100012
Asian6822441125458
Native Hawaiian or Other Pacific Islander01001
Black or African American2100012
White24770400951
More than one race21003
Unknown or Not Reported190010
Region of Enrollment
Region of Enrollment(Participants)Placebo IV Q4W300 mg Mirikizumab IV Q4WPlacebo IV Q4W ME2 Cohort300 mg Mirikizumab IV Q4W ME2 CohortTotal
Argentina380011
Australia4100014
Austria26008
Belgium36009
Canada11230034
China21641125184
Croatia11002
Czechia20350055
Denmark07007
France15490064
Germany6330039
Hungary7160023
India21620083
Ireland01001
Israel3140017
Italy12250037
Japan3510200137
Latvia6240030
Lithuania6160022
Malaysia06006
Mexico2100012
Netherlands290011
Poland3210400136
Romania2130015
Russia287900107
Serbia8130021
Slovakia3210024
South Korea5230028
Spain7150022
Switzerland290011
Taiwan03003
Turkey560011
Ukraine26680094
United Kingdom7110018
United States3611500151
08

Study locations

502 sites
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Dcr-Pi, Pc
    Litchfield Park, Arizona 85340, United States
  • Maricopa Integrated Health System
    Phoenix, Arizona 85008, United States
  • Physicians Research Group
    Tempe, Arizona 85284, United States
  • Yuma Gastro LLC
    Yuma, Arizona 85364, United States
  • Valley Gastroenterology
    Arcadia, California 91006, United States
  • Care Access Research
    Berkeley, California 94705, United States
  • Citrus Valley Health Partners
    Covina, California 91722, United States
  • Valley View Internal Medicine
    Garden Grove, California 92843, United States
  • Om Research, LLC
    Lancaster, California 93534, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • California Medical Research Associates
    Northridge, California 91324, United States
  • Gastroenterology Associates
    Pasadena, California 91105, United States
  • Clinical Applications Laboratories, Inc.
    San Diego, California 92103, United States
  • UCSF Medical Center at Mission Bay
    San Francisco, California 94158, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Delta Waves Sleep Disorders and Research Center
    Colorado Springs, Colorado 80918, United States
  • Gastroenterology Consultants of Clearwater
    Clearwater, Florida 33756, United States
  • West Central Gastroenterology d/b/a Gastro Florida
    Clearwater, Florida 33761, United States
  • Clinical Research of West Florida, Inc. (Clearwater)
    Clearwater, Florida 33765, United States
  • Pioneer Clinical Research
    Coral Springs, Florida 33067, United States
  • Direct Helpers Medical Center
    Hialeah, Florida 33012, United States
  • The Center for Gastrointestinal Disorders
    Hollywood, Florida 33021, United States
  • Nature Coast Clinical Research, LLC
    Inverness, Florida 34452, United States
  • SIH Research, LLC
    Kissimmee, Florida 34741, United States
  • Columbus Clinical Services, LLC
    Miami, Florida 33125, United States
  • Research Associates of South Florida, LLC
    Miami, Florida 33134, United States
  • IMIC, Inc.
    Miami, Florida 33176, United States
  • Inpatient Research Clinic, LLC
    Miami Lakes, Florida 33014, United States
  • Life Medical Center & Research, Inc
    Miami Lakes, Florida 33014, United States
  • Wellness Clinical Research
    Miami Lakes, Florida 33016, United States
  • Pharma Research International, Inc.
    Naples, Florida 34110, United States
  • Center for Interventional Endoscopy
    Orlando, Florida 32803, United States
  • Clintheory Healthcare
    Orlando, Florida 32818, United States
  • Gastroenterology Associates of Pensacola, PA
    Pensacola, Florida 32503, United States
  • Florida Digestive Specialist
    St. Petersburg, Florida 33709, United States
  • Florida Medical Clinic LLC
    Zephyrhills, Florida 33542-7505, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Gastrointestinal Diseases Research
    Columbus, Georgia 31904, United States
  • Atlanta Gastroenterology Specialists, PC
    Suwanee, Georgia 30024, United States
  • Grand Teton Research Group
    Idaho Falls, Idaho 83404, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • Texas Digestive Disease Consultants
    Baton Rouge, Louisiana 70809, United States
  • Clinical Trials of SWLA, LLC
    Lake Charles, Louisiana 70601, United States
  • Delta Research Partners LLC
    Monroe, Louisiana 71201, United States
  • Tulane Univ School of Med
    New Orleans, Louisiana 70112 2715, United States
  • Nola Research Works, LLC
    New Orleans, Louisiana 70125, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • Gastroenterology Associates of Western Michigan, P.L.C.
    Wyoming, Michigan 49519, United States
  • Huron Gastroenterology Associates
    Ypsilanti, Michigan 48197, United States
  • MNGI Digestive Health - Plymouth Endoscopy Center & Clinic
    Plymouth, Minnesota 55446, United States
  • Care Access Research LLC
    Jackson, Mississippi 39206, United States
  • Digestive Health Specialists
    Tupelo, Mississippi 38801, United States
  • Washington University Medical School
    St Louis, Missouri 63110, United States
  • Capital Health Medical Center Hopewell
    Pennington, New Jersey 08534, United States
  • Northwell Health
    Great Neck, New York 11021, United States
  • NYU Langone Long Island Clinical Research Associates
    Lake Success, New York 11042, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Carolina Digestive Diseases and Endoscopy Center
    Greenville, North Carolina 27834, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157-1045, United States
  • Trinity Health Center Medical Arts
    Minot, North Dakota 58701, United States
  • META Medical Research Institute, LLC
    Dayton, Ohio 45432, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Care Access Research - Youngstown
    Poland, Ohio 44514, United States
  • Great Lakes Medical Research, LLC
    Westlake, Ohio 44145, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Digestive Disease Associates
    Wyomissing, Pennsylvania 19610, United States
  • Ocean State Clinical Research Partners
    Lincoln, Rhode Island 02865, United States
  • Invocare Clinical Research Center
    Mauldin, South Carolina 29662, United States
  • Invocare Clinical Research Center
    West Columbia, South Carolina 29169, United States
  • Midwest Medical Care
    Sioux Falls, South Dakota 57108, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Galen Medical Group
    Hixson, Tennessee 37343, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Medical Branch at Galveston
    Galveston, Texas 77555, United States
  • Digestive Health Associates of Texas
    Garland, Texas 75044, United States
  • Houston Methodist Research Ins
    Houston, Texas 77030, United States
  • Biopharma Informatic, Inc.
    Houston, Texas 77043, United States
  • Gastroenterology Research of San Antonio
    San Antonio, Texas 78229, United States
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
  • Bandera Family Health Care
    San Antonio, Texas 78249, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • GI and Liver Research, LLC
    Webster, Texas 77598, United States
  • Care Access Research LLC - Salt Lake City
    Ogden, Utah 84403, United States
  • Care Access Research LLC - Salt Lake City
    Salt Lake City, Utah 84124, United States
  • Emeritas Research Group
    Leesburg, Virginia 20176, United States
  • Blue Ridge Medical Research
    Lynchburg, Virginia 24502, United States
  • The Gastroenterology Group, P.C.
    Reston, Virginia 20191, United States
  • Carilion Clinic
    Roanoke, Virginia 24016, United States
  • University of Washington Medical Center
    Seattle, Washington 98195-6424, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53215, United States
  • Allegiance Research Specialists, LLC
    Milwaukee, Wisconsin 53226, United States
  • Centro de Investigaciones Metabólicas (CINME)
    CABA, Buenos Aires C1027AAP, Argentina
  • Mautalen Salud e Investigacion-Centro de Osteopatías Médicas
    Ciudad Autonoma de Buenos Air, Buenos Aires C1128AAF, Argentina

Showing the first 100 of 502 sites across 35 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ran Z, Chen Y, Miao Y, Wang Y, Gao X, Zhong J, Ding X, Wang C, Zhang X, Ding Y, Hu N, Tang D, Yu J, Qian C, Shen J. Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials. BioDrugs. 2026 Jul;40(4):733-745. doi: 10.1007/s40259-026-00776-y. Epub 2026 May 12. PubMed 42120652 ↗
  • Hart A, Navabi S, D'Haens G, Matsuoka K, Martin-Arranz MD, Atreya R, Samaan KH, Dhesi E, Redondo I, Zhu B, Paulissen J, Zaremba-Pechmann L, Baygani S, Limdi J, Laharie D, Danese S. Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis. United European Gastroenterol J. 2026 May;14(4):e70214. doi: 10.1002/ueg2.70214. PubMed 42104877 ↗
  • Clemow DB, Dubinsky MC, Baygani SK, Sands BE, Keohane A, Danese S, Schreiber S, Walsh AJ, Hibi T, Gibble TH, Moses RE, Travis SPL. Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab. J Patient Rep Outcomes. 2025 Jul 1;9(1):75. doi: 10.1186/s41687-025-00906-0. PubMed 40591171 ↗
  • Panaccione R, Chan-Diehl F, Baygani S, Fisher DA, Moses RE, Siegmund B, Walsh A, Kobayashi T, Dulai PS, Travis S. Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis. Crohns Colitis 360. 2025 Jun 14;7(2):otaf043. doi: 10.1093/crocol/otaf043. eCollection 2025 Apr. PubMed 40589947 ↗
  • Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm Bowel Dis. 2025 Jul 7;31(7):1876-1890. doi: 10.1093/ibd/izae253. PubMed 39448057 ↗
  • Danese S, Dignass A, Matsuoka K, Ferrante M, Long M, Redondo I, Moses R, Maier S, Hunter Gibble T, Morris N, Milch C, Abreu MT. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme. J Crohns Colitis. 2024 Nov 4;18(11):1845-1856. doi: 10.1093/ecco-jcc/jjae088. PubMed 38869019 ↗
  • Friedrich S, Chua L, Adams DH, Crandall W, Zhang XC. Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies. Clin Pharmacol Ther. 2024 Aug;116(2):435-447. doi: 10.1002/cpt.3305. Epub 2024 May 26. PubMed 38797892 ↗
  • Long MD, Schreiber S, Hibi T, Gibble TH, Fisher DA, Park G, Moses RE, Higgins PDR, Lindsay JO, Lee SD, Escobar R, Jairath V. Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies. Crohns Colitis 360. 2024 Jan 6;6(1):otae001. doi: 10.1093/crocol/otae001. eCollection 2024 Jan. PubMed 38313767 ↗
  • Sands BE, Feagan BG, Hunter Gibble T, Traxler KA, Morris N, Eastman WJ, Schreiber S, Jairath V, Long MD, Armuzzi A. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies. Crohns Colitis 360. 2023 Nov 7;5(4):otad070. doi: 10.1093/crocol/otad070. eCollection 2023 Oct. PubMed 38034882 ↗
  • Chua L, Friedrich S, Zhang XC. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies. Clin Pharmacokinet. 2023 Oct;62(10):1479-1491. doi: 10.1007/s40262-023-01281-z. Epub 2023 Aug 23. PubMed 37610533 ↗
  • D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. PubMed 37379135 ↗
  • Magro F, Pai RK, Kobayashi T, Jairath V, Rieder F, Redondo I, Lissoos T, Morris N, Shan M, Park M, Peyrin-Biroulet L. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes. J Crohns Colitis. 2023 Oct 20;17(9):1457-1470. doi: 10.1093/ecco-jcc/jjad050. PubMed 37057827 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jan 2021, 31 months.

Results were first posted in Feb 2022, 1 year 1 month after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 31 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2018
First posted
May 8, 2018
StartActual
Jun 18, 2018
Primary completionActual
Jan 21, 2021
CompletionActual
May 15, 2024
Results first posted
Feb 28, 2022
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03518086
Responsible party
Sponsor
First posted
May 8, 2018
Start date
Jun 18, 2018
Primary completion
Jan 21, 2021
Completion
May 15, 2024
Results posted
Feb 28, 2022
Last update
May 31, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion